Lexaria Bioscience Corp
LEXX
|
$2.25
-3.85%
-4.0%
120K
|
Health Technology
(0.0% 1d) (-36.8% 1m) (6.4% 1y) (0.0% 2d) (0.0% 3d) (17.6% 7d) (50.42% volume)
Earnings Calendar:
Market Cap: $ 28,992,764
https://www.lexariaenergy.com
Sec Filling | Patents | 3 employees
Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide.
housing bloodstream education antiviral
add to watch list Paper trade email alert is off
Press-releases
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Published: 2024-03-14 (Crawled : 14:30) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.91%
H: 1.13%
C: -13.29%
RIGL | $1.06 -4.51% -4.72% 1.2M
|
Health Technology
|
| O: -0.69%
H: 1.39%
C: -7.64%
financial
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Published: 2024-03-07 (Crawled : 16:00) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 8.93%
H: 9.43%
C: 2.46%
contract awards pilot study
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 4.33%
H: 15.34%
C: 7.99%
animal diabetes study
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Published: 2024-02-15 (Crawled : 15:30) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -9.23%
nasdaq million direct offering
USD 46.90 billion growth opportunity in US-Cannabis Market between 2022 - 2027 | 21.92% YOY Growth Expected in 2023 | Technavio
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
TCNNF | $11.8 1.06% 380K
|
Process Industries
|
| O: -1.19%
H: 9.3%
C: 4.47%
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -9.23%
ACB | $6.555 13.21% 11.67% 8.9M
|
Process Industries
|
| O: 1.2%
H: 0.5%
C: -1.76%
SNDL | $1.835 0.27% 0.27% 3.3M
|
Process Industries
|
| O: -0.72%
H: 5.55%
C: 4.38%
JAZZ | $109.3 2.05% 2.01% 560K
|
Health Technology
|
| O: 0.26%
H: 3.55%
C: 3.48%
CRON | $2.51 -1.18% -1.2% 2.7M
|
Process Industries
|
| O: 0.47%
H: 5.19%
C: 3.77%
expected growth market
Lexaria Releases Annual Letter from the CEO - January 24, 2024
Published: 2024-01-24 (Crawled : 14:00) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 3.29%
H: 2.54%
C: 0.0%
ceo
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Published: 2024-01-11 (Crawled : 13:30) - globenewswire.com
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.69%
H: 5.52%
C: 4.83%
bioscience system bloodstream
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Published: 2024-01-09 (Crawled : 13:30) - globenewswire.com
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.73%
H: 4.86%
C: 2.9%
bioscience platform
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.71%
H: 0.36%
C: 0.11%
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.0%
H: 8.15%
C: 1.48%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.37%
H: 1.09%
C: 0.75%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.19%
H: 0.34%
C: 0.21%
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.32%
H: 0.26%
C: -0.18%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.28%
H: 0.99%
C: 0.93%
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: -1.54%
H: 9.38%
C: 8.59%
drug technology
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10